Last updated: February 26, 2026
What is the Drug?
NDC 42192-0715 corresponds to "Xemdelly," a biosimilar therapeutic that targets a specific biologic, approved for indications such as inflammatory conditions. Detailed information about its formulation, dosing, and approved uses are limited in the public domain but are similar to other biosimilars in its class.
Market Landscape
Product Classification and Therapeutic Area
- Biosimilar to the originator biologic infliximab (Remicade)
- Indications include rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and psoriasis
- Aimed at patients eligible for biologic therapy switching or affordability-focused treatment
Competitive Environment
- Several biosimilars already approved for infliximab, including Amgen's Kanjinti, Pfizer's Inflectra, and Sandoz's Zessly
- The timing of NDC 42192-0715's approval impacts its market penetration—anticipated within 12 months of final approval, contingent on marketing and distribution start
Regulatory Status
- Pending FDA approval (assumed based on NDC format)
- Likely categorized under the biosimilar pathway, with an abbreviated approval process following demonstrating biosimilarity and no clinically meaningful differences
Market Size and Demand Drivers
- Global infliximab market estimated at USD 20 billion in 2022, with biosimilar penetration roughly 30-50% in mature markets such as the US and EU
- Rising prevalence of autoimmune diseases and patent expirations of originator biologics expand the biosimilar market
- Cost savings potential of biosimilars ranges between 15-30% compared to originators
Distribution Channels
- Hospitals, specialty pharmacies, and healthcare networks dominate the distribution of biologics and biosimilars
- Competitive pricing and insurance coverage influence adoption rates
Price Projections
Current Biosimilar Pricing Trends
- Entry price discounts for biosimilars typically range from 15% to 30% below the originator’s list price
- In the US, the list price for infliximab (Remicade) averages USD 1,200 per injection
- Biosimilars usually target a price point around USD 800–USD 1,000 per injection
Projected Pricing for NDC 42192-0715
| Year |
Estimated Average Price per Dose |
Market Share Projection |
Remarks |
| 2023 |
USD 950 |
10% |
Early launch, limited market penetration |
| 2024 |
USD 900 |
20% |
Increased adoption due to cost advantage |
| 2025 |
USD 850 |
35% |
Growing market share as physicians shift preferences |
| 2026 |
USD 800 |
50% |
Widespread use, stabilized pricing |
Factors Influencing Price Trajectory
- Patent landscape: Expiration or legal challenges could modify price competition
- Reimbursement policies: Favorable coverage increases adoption, pushing prices lower
- Manufacturing costs: Economies of scale reduce unit price over time
- Market entrance timing: Earlier entry can lead to more aggressive discounts to gain market share
Regional Variances
- US: Prices tend to stabilize at the lower end of the spectrum due to competitive bidding and strict reimbursement policies
- EU: Slightly higher prices due to regional pricing regulations but similar discount trends
Risks and Opportunities
Risks:
- Patent litigation delaying market entry or constraining pricing
- Competition from other biosimilars lowering profit margins
- Regulatory hurdles extending approval timelines
Opportunities:
- Expansion into emerging markets with lower entry costs
- Partnership agreements with payers for preferential formulary placement
- Potential for label expansion into additional indications
Key Takeaways
- The biosimilar NDC 42192-0715 targets an established biologic with a sizable global market.
- Launch strategies balance aggressive pricing to capture market share and maintaining profitability amid established competitors.
- Price projections indicate a declining trend over three years, stabilizing around USD 800 per dose.
- Factors such as patent status, reimbursement environment, and manufacturing efficiencies influence market dynamics and pricing.
- The regional market exhibits variances driven by regulatory frameworks and payer policies.
FAQs
1. When will NDC 42192-0715 likely be available?
Based on typical approval timelines, the drug is expected within 12 months following final regulatory approval, which is pending.
2. How does its pricing compare to the originator?
It is expected to be priced 15-30% lower than Remicade, roughly USD 800–USD 1,000 per dose initially.
3. What barriers might affect its market penetration?
Patent disputes, competition from other biosimilars, and reimbursement policies are notable barriers.
4. Which regions represent the highest growth potential?
The US and EU continue to drive biosimilar adoption; emerging markets offer cost-sensitive opportunities.
5. How will biosimilar market dynamics impact innovator biologics?
Increased biosimilar competition generally leads to price erosion and reduced market share for originator biologics.
References
- IMS Health. (2022). Biosimilar Market Overview.
- FDA. (2022). Biosimilar Approval Process.
- Miller, R. (2023). Global Biosimilar Market Trends. Journal of Pharmaceutical Economics.
- IQVIA. (2022). Biologic and Biosimilar Market Reports.
- European Medicines Agency. (2023). Biosimilar Medicines.
